Fig. 4From: Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history databaseReason for the use of systemic mTOR inhibitor among patients with facial angiofibroma. mTOR, mechanistic target of rapamycin; LAM, lymphangioleiomyomatosis; SEGA, subependymal giant cell astrocytomaBack to article page